Curaleaf challenges Aurora Cannabis board’s rejection of its enhanced $5‑per‑share takeover offer
Curaleaf Holdings publicly disputed Aurora Cannabis’s board decision to reject its revised hostile bid, saying the offer values Aurora at a $5 per share price – an 86% premium to Aurora’s unaffected 30‑day VWAP and a 217% premium on an ex‑cash basis. Curaleaf accused the board of denying it due‑diligence access while allowing other parties to review confidential information. The company highlighted that Aurora had sold shares in July 2026 at $2.60 each, making the $5 offer a 92% premium to that price, and noted a 63% decline in Aurora’s adjusted EBITDA over the two most recent quarters.
Why it matters
The filing keeps the takeover dispute in shareholders’ view and pressures Aurora’s board to engage, as Curaleaf argues the bid provides a high premium and a favorable EBITDA multiple. The dispute may affect Aurora’s share price and the likelihood of any transaction before the offer deadline of December 4, 2026.
Key facts
- 1Curaleaf’s enhanced offer represents an 86% premium to Aurora’s unaffected 30‑day volume‑weighted average share price. prnewswire.com
- 2The same offer represents a 217% premium on an ex‑cash basis. prnewswire.com
- 3Curaleaf’s implied transaction multiple for Aurora is 14.3× 2026 Adjusted EBITDA, versus Curaleaf’s own 13.7× (IFRS). minichart.com.sg
- 4Aurora sold shares in July 2026 at $2.60 per share under its at‑the‑market program. minichart.com.sg
- 5Aurora’s Adjusted EBITDA declined 63% over its two most recent quarters. minichart.com.sg
- 6The revised offer proposes $5 per Aurora share, consisting of $1 in cash and 0.4013 Curaleaf shares, and remains open until December 4, 2026. themarijuanaherald.com
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.